Advances in the development of bacterial vector technology

Sims K Kochi; Kevin P Killeen; Una S Ryan

doi:10.1586/14760584.2.1.31

Back

Advances in the development of bacterial vector technology

Journal article

Peer reviewed

Advances in the development of bacterial vector technology

Sims K Kochi, Kevin P Killeen and Una S Ryan

Expert review of vaccines, Vol.2(1), pp.31-43

2003

DOI: https://doi.org/10.1586/14760584.2.1.31

PMID: 12901595

Files and links (1)

url

Published View

Published (Version of Record)

Abstract

attenuated bacteria

bacterial vector

BCG

Listeria

Salmonella

Shigella

Vibrio

vaccine

The demand for new and improved vaccines against human diseases has continued unabated over the past century. While the need continues for traditional vaccines in areas such as infectious diseases, there is an increasing demand for new therapies in nontraditional areas, such as cancer treatment, bioterrorism and food safety. Prompted by these changes, there has been a renewed interest in the application and development of live, attenuated bacteria expressing foreign antigens as vaccines. The application of bacterial vector vaccines to human maladies has been studied most extensively in attenuted strains of Salmonella. Live, attenuated strains of Shigella, Listeria monocytogenes, Mycobacterium bovis-BCG and Vibrio cholerae provide unique alternatives in terms of antigen delivery and immune presentation, however and also show promise as potentially useful bacterial vectors.

Details

Title: Advances in the development of bacterial vector technology
Authors/Creators: Sims K Kochi
Kevin P Killeen
Una S Ryan
Publication Details: Expert review of vaccines, Vol.2(1), pp.31-43
Identifiers: 991005579431207891
Murdoch Affiliation: Centre for Biosecurity and One Health
Language: English
Resource Type: Journal article

Metrics

47 Record Views